Company Filing History:
Years Active: 2018-2025
Title: The Innovations of Hanmi Xi: A Leader in Migraine Treatment
Introduction
Hanmi Xi, an accomplished inventor based in Furlong, PA, has made significant contributions to the pharmaceutical industry, particularly in the realm of migraine treatment. With a remarkable portfolio of five patents, Xi's work demonstrates a commitment to enhancing patient care and addressing complex health issues.
Latest Patents
Among Hanmi Xi's latest patents, the focus is primarily on pharmaceutical formulations for the treatment of migraine. The disclosed methods offer innovative approaches for the acute treatment of migraine with or without aura, utilizing ubrogepant as a key therapeutic agent. Notably, these methods consider specific patient populations, including those with hepatic impairment, renal impairment, and individuals concurrently taking CYP3A4 modulators, as well as BCRP and/or P-gp inhibitors. This tailored approach showcases the depth of Xi's research and his dedication to improving outcomes for various patient demographics.
Career Highlights
Hanmi Xi is currently associated with Merck Sharp & Dohme Corporation, a leading pharmaceutical company renowned for its contributions to medical science and public health. His work at Merck involves collaboration with other brilliant minds in the field, underscoring the importance of teamwork in the advancement of innovative treatments.
Collaborations
Throughout his career, Hanmi Xi has collaborated with several distinguished coworkers, including Mary Ann Johnson and Leonardo Resende Allain. These partnerships have allowed for the sharing of ideas and expertise, resulting in groundbreaking solutions for migraine management.
Conclusion
In conclusion, Hanmi Xi’s innovations represent a significant step forward in the field of migraine treatment. His dedication to improving therapeutic options for patients highlights the importance of innovation in medicine. As he continues to develop new methodologies, Xi's work is sure to have a lasting impact on the pharmaceutical industry and the lives of those who suffer from migraines.